ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2025-1-164-172ssmu-5975Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESРадионуклидная визуализация GRPR при злокачественной патологии молочной и предстательной желез: опыт клинического примененияRadionuclide GRPR imaging in malignant pathology of the mammary and prostate glands: clinical experiencehttps://orcid.org/0000-0001-5281-7758БрагинаО. Д.BraginaO. D.

Брагина Ольга Дмитриевна – д-р мед. наук, врач-онколог, вед. науч. сотрудник, отделение радионуклидной терапии и диагностики; ст. науч. сотрудник 

634009, г. Томск, пер. Кооперативный, 5;634050, Томск, пр. Ленина, 30

5, Kooperativny Lane, Tomsk, 634009;30, Lenin Av., Tomsk, 634050

bragina_od@mail.ruhttps://orcid.org/0009-0009-3775-9989ИвановаА. Г.IvanovaA. G.

Иванова Анастасия Григорьевна – врач-ординатор 

634009, г. Томск, пер. Кооперативный, 5;634050, Томск, Московский тракт, 2

5, Kooperativny Lane, Tomsk, 634009;2, Moscow Trakt, Tomsk, 634050

anfioran@yandex.ruhttps://orcid.org/0000-0001-7127-0188УсынинЕ. А.UsyninE. A.

Усынин Евгений Анатольевич – д-р мед. наук, зав. отделением общей онкологии 

634009, г. Томск, пер. Кооперативный, 5

5, Kooperativny Lane, Tomsk, 634009

gusi70@list.ruНаучно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук; Национальный исследовательский Томский политехнический университет (НИ ТПУ)РоссияCancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences; National Research Tomsk Polytechnic University (NR TPU)Russian FederationНаучно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук; Сибирский государственный медицинский университет (СибГМУ)РоссияCancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences; Siberian State Medical University (SibMed)Russian FederationНаучно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of SciencesRussian Federation202516042025241164172Copyright © Брагина О.Д., Иванова А.Г., Усынин Е.А., 20252025Брагина О.Д., Иванова А.Г., Усынин Е.А.Bragina O.D., Ivanova A.G., Usynin E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/5975

В лекции представлены актуальные клинические исследования относительно таргетной радионуклидной визуализации опухолей молочной и предстательной желез с гиперэкспрессией рецептора гастрин-высвобождающего пептида (GRPR). Рецептор GRPR представляет собой трансмембранный рецептор, активация которого способствует росту и пролиферации опухолевых клеток. Наиболее высокий уровень экспрессии GRPR наблюдается при таких злокачественных патологиях, как рак молочной и предстательной желез, что представляет особый интерес для радионуклидной диагностики. В проведенных клинических исследованиях оценивались безопасность, фармакологические свойства, эффективность визуализации радиофармпрепаратов на основе пептидов-агонистов и антагонистов GRPR, меченных радионуклидами технецием-99m и галлием-68. Результаты испытаний наглядно демонстрируют преимущество антагонистов GRPR перед агонистами GRPR, поскольку обладают оптимальными фармакологическими свойствами, хорошей переносимостью, быстрым выведением органами с физиологическим уровнем экспрессии рецептора, высокой эффективностью визуализации опухолей молочной и предстательной желез с гиперэкспрессией GRPR. 

In this lecture, we presented current clinical studies on targeted radionuclide imaging of breast and prostate tumors with overexpression of the gastrin-releasing peptide receptor (GRPR). The gastrin-releasing peptide receptor is a transmembrane receptor, the activation of which promotes the growth and proliferation of tumor cells. The highest level of GRPR expression is observed in malignant pathologies of breast and prostate, which is of particular interest for radionuclide diagnostics. The conducted clinical studies assessed the safety, pharmacological properties, and effectiveness of imaging of radiopharmaceuticals based on peptide agonists and antagonists of GRPR labeled with technetium-99m and gallium-68 radionuclides. The results clearly demonstrate the advantage of GRPR antagonists over GRPR agonists, since they have optimal pharmacological properties, good tolerability, rapid elimination by organs with a physiological level of receptor expression, and high imaging efficiency of mammary and prostate tumors with overexpression of GRPR.

GRPRтаргетная радионуклидная диагностикарак молочной железырак предстательной железыGRPRtargeted radionuclide diagnosticsbreast cancerprostate cancerРабота выполнена в рамках гранта Российского научного фThe work was carried out within the framework of the RNF grant No. 22-15-00169 on the topic “Phenotype of BRCA-like tumors in the process of carcinogenesis and treatment”.ReferencesSiegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics. CA Cancer J. Clin. 2022;72(1):7–33. DOI: 10.3322/caac.21708.Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics. CA Cancer J. Clin. 2022;72(1):7–33. DOI: 10.3322/caac.21708.Jensen R.T., Battey J.F., Spindel E.R., Benya R.V. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacological Reviews. 2008;60(1):1–42. DOI: 10.1124/pr.107.07108.Jensen R.T., Battey J.F., Spindel E.R., Benya R.V. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacological Reviews. 2008;60(1):1–42. DOI: 10.1124/pr.107.07108.Hohla F., Schally A.V. Targeting gastrin releasing peptide receptors: new options for the therapy and diagnosis of cancer. Cell Cycle. 2010;9(9):1738–1741. DOI: 10.4161/cc.9.9.11347.Hohla F., Schally A.V. Targeting gastrin releasing peptide receptors: new options for the therapy and diagnosis of cancer. Cell Cycle. 2010;9(9):1738–1741. DOI: 10.4161/cc.9.9.11347.D’Onofrio A., Engelbrecht S., Läppchen T., Rominger A., Gourni E. GRPR-targeting radiotheranostics for breast cancer management. Frontiers in Medicine. 2023;10:1250799. DOI: 10.3389/fmed.2023.1250799.D’Onofrio A., Engelbrecht S., Läppchen T., Rominger A., Gourni E. GRPR-targeting radiotheranostics for breast cancer management. Frontiers in Medicine. 2023;10:1250799. DOI: 10.3389/fmed.2023.1250799.Liu X., Carlisle D.L., Swick M.C., Gaither-Davis A., Grandis J.R., Siegfried J.M. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Experimental. Cell Research. 2007;313(7):1361–1372. DOI: 10.1016/j.yexcr.2007.01.016.Liu X., Carlisle D.L., Swick M.C., Gaither-Davis A., Grandis J.R., Siegfried J.M. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Experimental. Cell Research. 2007;313(7):1361–1372. DOI: 10.1016/j.yexcr.2007.01.016.Thomas S.M., Grandis J.R., Wentzel A.L., Gooding W.E., Lui V.W., Siegfried J.M. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia. 2005;7(4):426–431. DOI: 10.1593/neo.04454.Thomas S.M., Grandis J.R., Wentzel A.L., Gooding W.E., Lui V.W., Siegfried J.M. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia. 2005;7(4):426–431. DOI: 10.1593/neo.04454.Lui V.W., Thomas S.M., Zhang Q., Wentzel A.L., Siegfried J.M., Li J.Y. et al. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene. 2003;22(40):6183–6193. DOI: 10.1038/sj.onc.1206720.Lui V.W., Thomas S.M., Zhang Q., Wentzel A.L., Siegfried J.M., Li J.Y. et al. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene. 2003;22(40):6183–6193. DOI: 10.1038/sj.onc.1206720.Nagasaki S., Nakamura Y., Maekawa T., Akahira J., Miki Y., Suzuki T. et al. Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor βcx in human prostate carcinoma. Neoplasma. 2012;59(2):224–232. DOI: 10.4149/neo_2012_029.Nagasaki S., Nakamura Y., Maekawa T., Akahira J., Miki Y., Suzuki T. et al. Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor βcx in human prostate carcinoma. Neoplasma. 2012;59(2):224–232. DOI: 10.4149/neo_2012_029.Halmos G., Wittliff J.L., Schally A.V. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Research. 1995;55(2):280–287.Halmos G., Wittliff J.L., Schally A.V. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Research. 1995;55(2):280–287.Cornelio D.B., Roesler R., Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of Oncology. 2007;18(9):1457–1466. DOI: 10.1093/annonc/mdm058.Cornelio D.B., Roesler R., Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of Oncology. 2007;18(9):1457–1466. DOI: 10.1093/annonc/mdm058.Dalm S.U., Martens J.W.M., Sieuwerts A.M., van Deurzen C.H.M., Koelewijn S.J., de Blois E. et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. Journal of Nuclear Medicine. 2015;56(5):752–757. DOI: 10.2967/jnumed.114.153023.Dalm S.U., Martens J.W.M., Sieuwerts A.M., van Deurzen C.H.M., Koelewijn S.J., de Blois E. et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. Journal of Nuclear Medicine. 2015;56(5):752–757. DOI: 10.2967/jnumed.114.153023.Morgat C., MacGrogan G., Brouste V., Vélasco V., Sévenet N., Bonnefoi H. et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. Journal of Nuclear Medicine. 2017;58(9):1401–1407. DOI: 10.2967/jnumed.116.188011.Morgat C., MacGrogan G., Brouste V., Vélasco V., Sévenet N., Bonnefoi H. et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. Journal of Nuclear Medicine. 2017;58(9):1401–1407. DOI: 10.2967/jnumed.116.188011.Ozawa H. Principles and basics of immunohistochemistry. Folia Pharmacologica Japonica. 2019;154(4):156–164. DOI: 10.1254/fpj.154.156.Ozawa H. Principles and basics of immunohistochemistry. Folia Pharmacologica Japonica. 2019;154(4):156–164. DOI: 10.1254/fpj.154.156.Брагина О.Д., Чернов В.И., Гарбуков Е.Ю., Дорошенко А.В., Воробьева А.Г., Орлова А.М. и др. Возможности радионуклидной диагностики HER2-позитивного рака молочной железы с использованием меченных технецием-99m таргетных молекул: первый опыт клинического применения. Бюллетень сибирской медицины. 2021;20(1):23–30. DOI: 10.20538/1682-0363-2021-1-23-30.Брагина О.Д., Чернов В.И., Гарбуков Е.Ю., Дорошенко А.В., Воробьева А.Г., Орлова А.М. и др. Возможности радионуклидной диагностики HER2-позитивного рака молочной железы с использованием меченных технецием-99m таргетных молекул: первый опыт клинического применения. Бюллетень сибирской медицины. 2021;20(1):23–30. DOI: 10.20538/1682-0363-2021-1-23-30.Брагина О.Д., Деев С.М., Чернов В.И., Толмачев В.М. Эволюция таргетной радионуклидной диагностики HER2-позитивного рака молочной железы. Acta Naturae. 2022;14(2):4–15. DOI: 10.32607/actanaturae.11611.Брагина О.Д., Деев С.М., Чернов В.И., Толмачев В.М. Эволюция таргетной радионуклидной диагностики HER2-позитивного рака молочной железы. Acta Naturae. 2022;14(2):4–15. DOI: 10.32607/actanaturae.11611.Толмачев В.М., Чернов В.И., Деев С.М. Таргетная ядерная медицина. Найти и уничтожить. Успехи химии. 2022;91(3):RCR5034. DOI: 10.1070/RCR5034.Толмачев В.М., Чернов В.И., Деев С.М. Таргетная ядерная медицина. Найти и уничтожить. Успехи химии. 2022;91(3):RCR5034. DOI: 10.1070/RCR5034.Bragina O.D., Tashireva L.A, Loos D.M., Chernov V.I., Hober S., Tolmachev V.M. Evaluation of approaches for the assessment of HER2 expression in breast cancer by radionuclide imaging using the scaffold protein [99mTc]Tc-ADAPT6. Pharmaceutics. 2024;16(4):445. DOI: 10.3390/pharmaceutics16040445.Bragina O.D., Tashireva L.A, Loos D.M., Chernov V.I., Hober S., Tolmachev V.M. Evaluation of approaches for the assessment of HER2 expression in breast cancer by radionuclide imaging using the scaffold protein [99mTc]Tc-ADAPT6. Pharmaceutics. 2024;16(4):445. DOI: 10.3390/pharmaceutics16040445.Bragina O., Chernov V., Schulga A., Konovalova E., Hober S., Deyev S. et al. Direct intra-patient comparison of scaffold protein-based tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for imaging of HER2-positive breast cancer. Cancers. 2023;15(12):3149. DOI: 10.3390/cancers15123149.Bragina O., Chernov V., Schulga A., Konovalova E., Hober S., Deyev S. et al. Direct intra-patient comparison of scaffold protein-based tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for imaging of HER2-positive breast cancer. Cancers. 2023;15(12):3149. DOI: 10.3390/cancers15123149.Li X., Cai H., Wu X., Li L., Wu H., Tian R. New frontiers in molecular imaging using peptide-based radiopharmaceuticals for prostate cancer. Frontiers in Chemistry. 2020;8. DOI: 10.3389/fchem.2020.583309.Li X., Cai H., Wu X., Li L., Wu H., Tian R. New frontiers in molecular imaging using peptide-based radiopharmaceuticals for prostate cancer. Frontiers in Chemistry. 2020;8. DOI: 10.3389/fchem.2020.583309.Mansi R., Nock B.A., Dalm S.U., Busstra M.B., van Weerden W.M., Maina T. Radiolabeled bombesin analogs. Cancers. 2021;13(22):5766. DOI: 10.3390/cancers13225766.Mansi R., Nock B.A., Dalm S.U., Busstra M.B., van Weerden W.M., Maina T. Radiolabeled bombesin analogs. Cancers. 2021;13(22):5766. DOI: 10.3390/cancers13225766.Van de Wiele C., Dumont F., Vanden Broecke R., Oosterlinck W., Cocquyt V., Serreyn R. et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. European Journal of Nuclear Medicine. 2000;27(11):1694–1699. DOI: 10.1007/s002590000355.Van de Wiele C., Dumont F., Vanden Broecke R., Oosterlinck W., Cocquyt V., Serreyn R. et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. European Journal of Nuclear Medicine. 2000;27(11):1694–1699. DOI: 10.1007/s002590000355.Scopinaro F., De Vincentis G., Varvarigou A.D., Laurenti C., Iori F., Remediani S. et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30(10):1378–1382. DOI: 10.1007/s00259-003-1261-7.Scopinaro F., De Vincentis G., Varvarigou A.D., Laurenti C., Iori F., Remediani S. et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30(10):1378–1382. DOI: 10.1007/s00259-003-1261-7.Nock B.A., Nikolopoulou A., Galanis A., Cordopatis P., Waser B., Reubi J.-C. et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. Journal of Medicinal Chemistry. 2004;48(1):100–110. DOI: 10.1021/jm049437y.Nock B.A., Nikolopoulou A., Galanis A., Cordopatis P., Waser B., Reubi J.-C. et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. Journal of Medicinal Chemistry. 2004;48(1):100–110. DOI: 10.1021/jm049437y.Mather S.J., Nock B.A., Maina T., Gibson V., Ellison D., Murray I. et al. GRP receptor imaging of prostate cancer using [99mTc]Demobesin 4: a first-in-man study. Molecular Imaging and Biology. 2014;16(6):888–895. DOI: 10.1007/s11307-014-0754-z.Mather S.J., Nock B.A., Maina T., Gibson V., Ellison D., Murray I. et al. GRP receptor imaging of prostate cancer using [99mTc]Demobesin 4: a first-in-man study. Molecular Imaging and Biology. 2014;16(6):888–895. DOI: 10.1007/s11307-014-0754-z.Baum R.P., Prasad V., Mutloka N., Frischknecht M., Maecke H.R., Reubi J.C. Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: First results. The Journal of Nuclear Medicine. 2007;48.Baum R.P., Prasad V., Mutloka N., Frischknecht M., Maecke H.R., Reubi J.C. Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: First results. The Journal of Nuclear Medicine. 2007;48.Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V. et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. Journal of Nuclear Medicine. 2008;49(2):318–326. DOI: 10.2967/jnumed.107.045054.Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V. et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. Journal of Nuclear Medicine. 2008;49(2):318–326. DOI: 10.2967/jnumed.107.045054.Maina T., Bergsma H., Kulkarni H.R., Mueller D., Charalambidis D., Krenning E.P. et al. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2015;43(5):964–973. DOI: 10.1007/s00259-015-3232-1.Maina T., Bergsma H., Kulkarni H.R., Mueller D., Charalambidis D., Krenning E.P. et al. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2015;43(5):964–973. DOI: 10.1007/s00259-015-3232-1.Minamimoto R., Sonni I., Hancock S., Vasanawala S., Loening A., Gambhir S.S. et al. Prospective evaluation of 68GaRM2 PET/MRI in patients with biochemical recurrence of prostate cancer and negative findings on conventional imaging. Journal of Nuclear Medicine. 2017;59(5):803–808. DOI: 10.2967/jnumed.117.197624.Minamimoto R., Sonni I., Hancock S., Vasanawala S., Loening A., Gambhir S.S. et al. Prospective evaluation of 68GaRM2 PET/MRI in patients with biochemical recurrence of prostate cancer and negative findings on conventional imaging. Journal of Nuclear Medicine. 2017;59(5):803–808. DOI: 10.2967/jnumed.117.197624.Duan H., Baratto L., Fan R.E., Soerensen S.J.C., Liang T., Chung B.I. et al. Correlation of68Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed intermediate- or high-risk prostate cancer. Journal of Nuclear Medicine. 2022;63(12):1829–1835. DOI: 10.2967/jnumed.122.263971.Duan H., Baratto L., Fan R.E., Soerensen S.J.C., Liang T., Chung B.I. et al. Correlation of68Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed intermediate- or high-risk prostate cancer. Journal of Nuclear Medicine. 2022;63(12):1829–1835. DOI: 10.2967/jnumed.122.263971.Zhang J., Niu G., Fan X., Lang L., Hou G., Chen L. et al. PET using a GRPR antagonist 68Ga-RM26 in healthy volunteers and prostate cancer patients. Journal of Nuclear Medicine. 2017;59(6):922–928. DOI: 10.2967/jnumed.117.198929.Zhang J., Niu G., Fan X., Lang L., Hou G., Chen L. et al. PET using a GRPR antagonist 68Ga-RM26 in healthy volunteers and prostate cancer patients. Journal of Nuclear Medicine. 2017;59(6):922–928. DOI: 10.2967/jnumed.117.198929.Chernov V., Rybina A., Zelchan R., Medvedeva A., Bragina O., Lushnikova N. et al. Phase I trial of [99mTc]TcmaSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors. Cancers. 2023;15(6):1631. DOI: 10.3390/cancers15061631.Chernov V., Rybina A., Zelchan R., Medvedeva A., Bragina O., Lushnikova N. et al. Phase I trial of [99mTc]TcmaSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors. Cancers. 2023;15(6):1631. DOI: 10.3390/cancers15061631.Nock B.A., Kaloudi A., Lymperis E., Giarika A., Kulkarni H.R., Klette I. et al. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. Journal of Nuclear Medicine. 2016;58(1):75–80. DOI: 10.2967/jnumed.116.178889.Nock B.A., Kaloudi A., Lymperis E., Giarika A., Kulkarni H.R., Klette I. et al. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. Journal of Nuclear Medicine. 2016;58(1):75–80. DOI: 10.2967/jnumed.116.178889.Djaileb L., Morgat C., van der Veldt A., Virgolini I., Cortes F., Demange A. et al. Preliminary diagnostic performance of [68Ga]-NeoBOMB1 in patients with gastrin-releasing peptide receptor-positive breast, prostate, colorectal or lung tumors (Neofind). Journal of Nuclear Medicine. 2020;61(Suppl. S1):346.Djaileb L., Morgat C., van der Veldt A., Virgolini I., Cortes F., Demange A. et al. Preliminary diagnostic performance of [68Ga]-NeoBOMB1 in patients with gastrin-releasing peptide receptor-positive breast, prostate, colorectal or lung tumors (Neofind). Journal of Nuclear Medicine. 2020;61(Suppl. S1):346.Van de Wiele C., Phonteyne P., Pauwels P., Goethals I., Van den Broecke R., Cocquyt V. et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. Journal of Nuclear Medicine. 2008;49(2):260–264. DOI: 10.2967/jnumed.107.047167.Van de Wiele C., Phonteyne P., Pauwels P., Goethals I., Van den Broecke R., Cocquyt V. et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. Journal of Nuclear Medicine. 2008;49(2):260–264. DOI: 10.2967/jnumed.107.047167.Scopinaro F., Varvarigou A., Ussof W., De Vincentis G., Archimandritis S., Evangelatos G. et al. Breast cancer takes up 99mTc Bombesin. A preliminary report. Tumori Journal. 2002;88(3):S25–S28. DOI: 10.1177/030089160208800331.Scopinaro F., Varvarigou A., Ussof W., De Vincentis G., Archimandritis S., Evangelatos G. et al. Breast cancer takes up 99mTc Bombesin. A preliminary report. Tumori Journal. 2002;88(3):S25–S28. DOI: 10.1177/030089160208800331.Urbano N., Scimeca M., Tancredi V., Bonanno E., Schillaci O. 99mTc-sestamibi breast imaging: current status, new ideas and future perspectives. Seminars in Cancer Biology. 2022;84:302–309. DOI: 10.1016/j.semcancer.2020.01.007.Urbano N., Scimeca M., Tancredi V., Bonanno E., Schillaci O. 99mTc-sestamibi breast imaging: current status, new ideas and future perspectives. Seminars in Cancer Biology. 2022;84:302–309. DOI: 10.1016/j.semcancer.2020.01.007.Stoykow C., Erbes T., Maecke H.R., Bulla S., Bartholomä M., Mayer S. et al. Gastrin-releasing peptide receptor imaging in breast cancer using the receptor fntagonist 68Ga-RM2 and PET. Theranostics. 2016;6(10):1641–1650. DOI: 10.7150/thno.14958.Stoykow C., Erbes T., Maecke H.R., Bulla S., Bartholomä M., Mayer S. et al. Gastrin-releasing peptide receptor imaging in breast cancer using the receptor fntagonist 68Ga-RM2 and PET. Theranostics. 2016;6(10):1641–1650. DOI: 10.7150/thno.14958.Morgat C., Schollhammer R., Macgrogan G., Barthe N., Vélasco V., Vimont D. et al. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PloS One. 2019;14(1):e0210905. DOI: 10.1371/journal.pone.0210905.Morgat C., Schollhammer R., Macgrogan G., Barthe N., Vélasco V., Vimont D. et al. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PloS One. 2019;14(1):e0210905. DOI: 10.1371/journal.pone.0210905.Zang J., Mao F., Wang H., Zhang J., Liu Q., Peng L. et al. 68Ga-NOTA-RM26 PET/CT in the evaluation of breast cancer. Clinical Nuclear Medicine. 2018;43(9):663–669. DOI: 10.1097/rlu.0000000000002209.Zang J., Mao F., Wang H., Zhang J., Liu Q., Peng L. et al. 68Ga-NOTA-RM26 PET/CT in the evaluation of breast cancer. Clinical Nuclear Medicine. 2018;43(9):663–669. DOI: 10.1097/rlu.0000000000002209.Kanellopoulos P., Mattsson A., Abouzayed A., Obeid K., Nock B A., Tolmachev V. et al. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI Radiopharmacy and Chemistry. 2024;9(1). DOI: 10.1186/s41181-024-00242-6.Kanellopoulos P., Mattsson A., Abouzayed A., Obeid K., Nock B A., Tolmachev V. et al. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI Radiopharmacy and Chemistry. 2024;9(1). DOI: 10.1186/s41181-024-00242-6.Nock B.A., Kaloudi A., Kanellopoulos P., Janota B., Bromińska B., Iżycki D. et al. [99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes. Cancers. 2015;13(20):5093. DOI: 10.3390/cancers13205093.Nock B.A., Kaloudi A., Kanellopoulos P., Janota B., Bromińska B., Iżycki D. et al. [99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes. Cancers. 2015;13(20):5093. DOI: 10.3390/cancers13205093.

The authors declare that there are no conflicts of interest present.